Mountain Pacific Investment Advisers LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 41,926 shares of the medical research company's stock after selling 685 shares during the quarter. Thermo Fisher Scientific makes up 1.6% of Mountain Pacific Investment Advisers LLC's investment portfolio, making the stock its 25th largest holding. Mountain Pacific Investment Advisers LLC's holdings in Thermo Fisher Scientific were worth $20,862,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $3,149,754,000. GAMMA Investing LLC increased its position in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after buying an additional 2,415,346 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after buying an additional 1,433,444 shares during the period. Kovitz Investment Group Partners LLC increased its position in Thermo Fisher Scientific by 1,905.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after buying an additional 858,193 shares during the period. Finally, Proficio Capital Partners LLC increased its position in Thermo Fisher Scientific by 68,617.0% in the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after buying an additional 761,649 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Thermo Fisher Scientific Price Performance
NYSE:TMO traded up $2.28 during trading hours on Thursday, reaching $392.54. The company had a trading volume of 2,883,201 shares, compared to its average volume of 1,944,785. The stock has a 50-day moving average of $414.12 and a two-hundred day moving average of $489.73. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The firm has a market capitalization of $148.18 billion, a PE ratio of 23.02, a PEG ratio of 2.06 and a beta of 0.78. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.11 earnings per share. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.
Insiders Place Their Bets
In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.33% of the company's stock.
Analyst Ratings Changes
Several research analysts have commented on TMO shares. UBS Group dropped their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Finally, Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $605.30.
Read Our Latest Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
